Mortality associated with cefepime therapy among neutropenic patients

Clinical Infectious Diseases

Volumn 49, Issue 6, 2009, Pages 987-

  Gomez, M Lucia ^a   Quintana, Salvador ^a   Garau, Javier ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; HUMAN; LETTER; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CAUSE OF DEATH; CEPHALOSPORINS; HUMANS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 70049094022     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605535     Document Type: Letter

References (3)

1. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systemic review and meta-analysis. Lancet Infect Dis 2007;7:338-418 (Pubitemid 46591956)
2. Nguyen TD, Williams B, Trang E. Cefepime therapy and all-cause mortality. Clin Infect Dis 2009;48:902-911
3. Gomez L, Estrada C, Gomez I, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin in the treatment of patients with fever and granulocytopenia [abstract L-771 ]. In: Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). 2001.